916764-89-1

Basic information

• Product Name: 6-CHLORO-1-[(4-METHOXYPHENYL)METHYL]-3-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE
• Synonyms: 6-CHLORO-1-[(4-METHOXYPHENYL)METHYL]-3-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE;6-Chloro-1-(4-Methoxybenzyl)-3-Methylpyrimidine-2,4(1H,3H)-Dione;6-Chloro-1-(4-Methoxybenzyl)-3-Methylpyrimidine-2,4(1H,3H)-Dione(WXC01630)
• CAS NO: 916764-89-1
• Molecular Formula: C₁₃H₁₃ClN₂O₃
• Molecular Weight: 280.71
• Mol File: 916764-89-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 398.7±52.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• PKA: -3?+-.0.40(Predicted)
• CAS DataBase Reference: 6-CHLORO-1-[(4-METHOXYPHENYL)METHYL]-3-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-1-[(4-METHOXYPHENYL)METHYL]-3-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE(916764-89-1)
• EPA Substance Registry System: 6-CHLORO-1-[(4-METHOXYPHENYL)METHYL]-3-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE(916764-89-1)

Safety Data

• Hazardous Substances Data: 916764-89-1(Hazardous Substances Data)

Usage

General Description

6-CHLORO-1-[(4-METHOXYPHENYL)METHYL]-3-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE is a chemical compound with the molecular formula C14H13ClN2O3. 6-CHLORO-1-[(4-METHOXYPHENYL)METHYL]-3-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE belongs to the class of pyrimidine derivatives and contains a chloro group, a methyl group, and a methoxyphenylmethyl group. It is used in the synthesis of pharmaceutical drugs and has potential therapeutic applications, particularly in the treatment of neurological disorders and inflammatory conditions. 6-CHLORO-1-[(4-METHOXYPHENYL)METHYL]-3-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE may also have other industrial or research applications, such as in the development of new materials or chemicals. However, it is important to handle this compound with caution and in accordance with proper safety protocols, as it may have potential hazards associated with its use.

Upstream product

• 2565-47-1 1-methyl-2,4,6-pyrimidinetrione 
• 4318-56-3 3-methyl-6-chlorouracil 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1160521-51-6 7-(4-methoxybenzyl)-5-methyl-3-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 
• 916765-00-9 6-(2-(biphenyl-4-ylmethylene)hydrazinyl)-1-(4-methoxybenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione 
• 916765-03-2 3-benzyl-2-(biphenyl-4-ylmethyl)-6-chloro-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 916765-04-3 3-benzyl-2-(biphenyl-4-ylmethyl)-6-(1-hydroxy-2-methylpropan-2-ylimino)-5-methyl-6,7-dihydro-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 916765-01-0 3-benzyl-2-(biphenyl-4-ylmethyl)-7-(4-methoxybenzyl)-5-methyl-2H-pyrazolo[3,4-d]lpyrimidine-4,6(5H,7H)-dione 

Relevant articles and documents

Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors

Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. With the assistance of molecular docking and dynamics simulations, we designed and synthesized a novel series of pyrazolopyrimidone derivatives as effective and metabolically stable inhibitors against PDE1. Most compounds have good inhibitory activities against PDE1 at the concentration of 20 nM. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat liver microsomes (RLM) (t1/2 of 28.5 min), indicating that compound 2j can be used as a tool to explore the molecular recognition mechanism between inhibitors and the target protein PDE1.

Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases

A diverse set of 3-aminopyrazolo[3,4-d]pyrimidinones was designed and synthesized. The structure-activity relationships of these polycyclic compounds as phosphodiesterase 1 (PDE1) inhibitors were studied along with their physicochemical and pharmacokinetic properties. Systematic optimizations of this novel scaffold culminated in the identification of a clinical candidate, (6aR,9aS)-2-(4-(6-fluoropyridin-2-yl)benzyl)-5-methyl-3-(phenylamino)-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4-(2H)-one phosphate (ITI-214), which exhibited picomolar inhibitory potency for PDE1, demonstrated excellent selectivity against all other PDE families and showed good efficacy in vivo. Currently, this investigational new drug is in Phase I clinical development and being considered for the treatment of several indications including cognitive deficits associated with schizophrenia and Alzheimer's disease, movement disorders, attention deficit and hyperactivity disorders, and other central nervous system (CNS) and non-CNS disorders.

FREE BASE CRYSTALS

The present invention relates to crystals of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one, and methods of making and using such crystals.